Partnerships Viatris: strategic collaboration (2015) for development/commercialization of revefenacin; Viatris holds exclusive rights in China and adjacent territories (Hong Kong SAR, Macau SAR, Taiwan)
Indications
COPD (maintenance treatment)(Approved)
Status note Revefenacin inhalation solution, FDA-approved for maintenance treatment of COPD in the US.
Ampreloxetine
Phase 3 · TerminatedModality: small molecule (oral, once-daily)
Target NET
Partnerships Royalty Pharma: contingent funding in exchange for future royalty rights
Indications
symptomatic neurogenic orthostatic hypotension in multiple system atrophy (CYPRESS)(Phase 3)
Status note Once-daily norepinephrine reuptake inhibitor for nOH in MSA. SEQUOIA (2021) and REDWOOD (2022) Phase 3 studies missed their primary endpoints; CYPRESS Phase 3 topline (March 3, 2026) missed its primary endpoint, and the company decided to wind down the ampreloxetine program.
Per-asset detail extracted from the 10-Q filed 2026-08-11. Fields the filing does not state are marked "not disclosed" rather than filled from other sources.
Sponsor-matched active trials from ClinicalTrials.gov (0 as sponsor, 1 as collaborator); "Sponsor" = company is the lead sponsor, "Collaborator" = company is a collaborator. The BP column flags big-pharma involvement as lead sponsor or collaborator (excluding the company itself). The Mgmt guide column shows what management guided for readout timing when a guided program matches the trial (hover for the quote, click for the source). Trial listings are not a company pipeline slide.